(1) 神经退行性疾病病理机制及药物靶点研究
(2) 心血管疾病病理机制及药物靶点研究
(3) 糖尿病病理机制及药物靶点研究

1、科研项目
(1) 国家自然科学基金青年项目，81703520，Nrf2在II型糖尿病引起的阿尔茨海默症的发病和治疗中的作用和机制研究， 2018/01-2020/12，20.10万，结题，主持。
(2) 宁夏回族自治区重点研发计划项目申请书（重点项目），2019BFG02017，基于 Keap1-Nrf2 蛋白相互作用新型磺酰胺类抗认知功能障碍先导化合物的优化及成药性研究，2019/01-2021/12，409万，结题，合作单位主持。
2、代表性科研成果
筛选获得数个化合物，并在阿尔兹海默病动物及细胞模型上验证药效，研究作用机制及体内药物代谢过程

(1) Yi Sun#, Jue Wang#, Wenxin Ding#, Qingqing Qin#, Rui Wang, Ruizhi Yu, Jianyu Yan, Ruilin Hou, Guodong Liu, Xiangming Cai, Zhuo Qu, Wannian Zhang, Jianqiang Yu, Chengguo Xing, Chunlin Zhuang*. Design of Anti-depressant Phosphodiester Amino Acidic Keap1-Nrf2 Protein-Protein Interaction Inhibitors. Redox Biol. 2025; 82:103620.
(2) Yi Sun#, Lijuan Xu#, Dongpeng Zheng, Jue Wang, Guodong Liu, Zixin Mo, Chao Liu, Wannian Zhang, Jianqiang Yu, Chengguo Xing, Ling He*, Chunlin Zhuang*. A potent phosphodiester Keap1-Nrf2 protein-protein interaction inhibitor as the efficient treatment of Alzheimer’s disease. Redox Biol. 2023; 64:102793.
(3) Yi Sun#, Lijuan Xu#, Hongming Shao, Danni Quan, Zixin Mo, Jue Wang, Wannian Zhang, Jianqiang Yu, Chunlin Zhuang*, Ke Xu*. Discovery of a trifluoromethoxy cyclopentanone benzothiazole receptor-interacting protein kinase 1 (RIPK1) inhibitor as the treatment of Alzheimers Disease. J Med Chem. 2022; 10;65(21):14957-14969.
(4) Yitong Chen#, Qingqing Qin#, Wenxin Ding#, Ruizhi Yu, Rui Wang, Hualong Ji, Jianyu Yan, Hao Ma, Cheng-Shi Jiang*, Yi Sun*, Chunlin Zhuang*. Design of spiro-heterocyclic substituted diaminonaphthalene Keap1-Nrf2 protein-protein interaction inhibitors as novel anti-depressant agents. Eur J Med Chem. 2025; 296:117848.
(5) Yi Sun#, Chao Liu, Ling He*. Adenosine A2A receptor antagonist SCH58261 improves the cognitive function in Alzheimer’s disease model mice through activation of Nrf2 via an autophagy-dependent pathway. Antioxid Redox Signal. 2024; 41(16-18):1117-1133.